Genentech Cancer Antibody, Son of Rituxan, Nails Pivotal Study Xconomy Genentech has been searching for years to find a way to improve upon rituximab (Rituxan), which set a gold standard 15 years ago as part of the first generation of targeted antibody cancer drugs. Now it looks like Genentech has finally nailed a new and ... Roche Experimental Leukemia Drug Helps Shrink Tumors Genentech's Obinutuzumab (GA101) Significantly Reduced the Risk of Disease ... |
